The Company's leases do not indicate the rate implicit in the lease. As such, the Company has used its incremental borrowing rate, determined based on market indications of the rate at which the Company could borrow, adjusted for the term, value and payment schedule of individual leases, at the effective date for ASC 842 or at the lease commencement date for leases entered into after January 1, 2019. Lease expense, charged to selling, general and administrative expense, for the year ended December 31, 2021 and 2020 consisted of: Year Ended December 31, 2021 2020 Operating lease cost $ 2,308 $ 2,428 Short-term lease cost 738 961 Variable cost 590 502 Sublease income (74) (212) Total lease cost $ 3,562 $ 3,679 Other information regarding the Company's leases: Year Ended December 31, 2021 2020 Operating cash flows for operating leases $ (2,717) $ (2,767) Right-of-use assets obtained in exchange for new operating lease liabilities $ — $ 319 Operating lease liabilities arising from obtaining right-of-use assets $ — $ 387 Weighted average remaining lease term - operating leases 4.3 years 5.0 years Weighted average discount rate - operating leases 11 % 11 % As of December 31, 2021 and 2020, the Company had no finance leases. As of December 31, 2021, the remaining lives of the Company's operating leases ranged from one to eight years. Maturities of the Company's operating leases at December 31, 2021 were as follows: Amounts 2022 $ 2,677 2023 2,686 2024 2,531 2025 678 2026 609 Thereafter 1,087 Total future minimum lease payments 10,268 Less: imputed interest (2,108) Total $ 8,160 As reported in the Consolidated Balance Sheet Accrued and other current liabilities $ 1,912 Operating lease liabilities 6,248 $ 8,160 NantHealth, Inc. Notes to Consolidated Financial Statements (Dollars in thousands, except per share amounts) - 122 -
RkJQdWJsaXNoZXIy NTIzOTM0